Which pharmaceutical company develops and manufactures adagrasib (Krazati)?

Adagrasiib (Krazati) is an oral small molecule targeted drug targeting the KRAS G12C mutation, developed by the American company Mirati Therapeutics. Mirati Therapeutics is an innovative biopharmaceutical company focusing on precision targeted therapy of tumors. It has rich R&D experience and clinical research accumulation in the KRAS targeting field. Relying on its independent research and development platform and advanced molecular design technology, the company successfully promoted adagrasibu into clinical practice and verified its efficacy and safety in multiple international clinical trials.

In terms of production qualifications, Mirati Therapeutics entrusts pharmaceutical companies with international GMP certification to produce adagrasib. These manufacturing companies all comply with the pharmaceutical manufacturing quality management practices (GMP) of the United StatesFDA and the European Union EMA. They have strict standardized management from raw material procurement, production process, quality testing to finished product packaging to ensure that each batch of drugs meets pharmacopoeia standards and clinical use requirements.

The R&D and production processes of adagrasib are subject to multiple quality controls at the same time. During the research and development stage, Mirati ensures that the drug molecular structure is stable and has good pharmacokinetic properties through rigorous medicinal chemistry analysis, stability studies and preclinical safety assessments. During the production stage, drugs need to undergo high-precision testing, including active ingredient content, purity, dissolution, impurity levels and other indicators to ensure drug quality and clinical safety.

In addition, adagrasib is also subject to strict supervision in its listing and circulation. Drug regulatory agencies in various countries (such as FDA, EMA) conduct continuous reviews of their clinical trial data, production processes, post-marketing adverse reaction monitoring and risk management plans (RMP) to ensure the safety and consistency of efficacy of drugs for patients. Through high-level R&D and production qualification assurance, adagrasib provides reliable and standardized treatment options for patients with KRAS G12C mutation-positive advanced tumors.

Reference link:https://www.drugs.com